LSDP5 Activators
LSDP5 Activators represent a novel and intriguing class of chemical compounds characterized by their ability to modulate specific neural pathways associated with sensory perception and cognitive functions. Structurally, LSDP5 Activators share a distinct molecular framework, featuring a core scaffold with unique functional groups that interact with receptors in the central nervous system. This class of compounds is renowned for inducing profound alterations in sensory perception, often leading to vivid hallucinations, intensified emotions, and alterations in the perception of time and space.
The pharmacological effects of LSDP5 Activators are primarily attributed to their interaction with serotonin receptors, particularly the 5-HT2A subtype. By binding to these receptors, these compounds elicit a cascade of neurochemical events that disrupt the usual transmission of serotonin, resulting in the characteristic psychedelic experiences associated with their use. Moreover, LSDP5 Activators demonstrate a high affinity for specific glutamate receptors, influencing neural excitability and synaptic plasticity. This dual mechanism of action contributes to the unique and profound alterations in consciousness observed during their administration. As research into the pharmacology and neurobiology of LSDP5 Activators advances, a deeper understanding of their specific molecular interactions and their impact on neural circuits is expected to emerge, shedding light on the intricate mechanisms underlying altered states of consciousness induced by this distinct chemical class.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels which in turn activate PKA. PKA phosphorylation may lead to changes in the function of target proteins such as LSDP5, by altering its interaction with lipid droplets and enhancing its role in lipid metabolism. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
As a synthetic catecholamine, Isoproterenol activates beta-adrenergic receptors, stimulating adenylate cyclase and increasing cAMP levels. Elevated cAMP activates PKA, which can then phosphorylate LSDP5, potentially enhancing its activity in lipid storage regulation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR is an activator of AMPK, which is involved in energy homeostasis. AMPK activation can lead to the phosphorylation of lipid-associated proteins, including LSDP5, thereby enhancing its role in the mobilization and breakdown of lipids. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
As a PPARγ agonist, Rosiglitazone influences genes involved in lipid metabolism. Activated PPARγ may enhance the function of LSDP5 by upregulating its expression and promoting its activity in lipid processing within adipocytes. | ||||||
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $193.00 $357.00 | 13 | |
SRT1720 is a SIRT1 activator, which is known to regulate metabolic pathways. The activation of SIRT1 could lead to deacetylation of proteins involved in lipid metabolism, potentially enhancing LSDP5's role in lipolysis and energy expenditure. | ||||||
L-165041 | 79558-09-1 | sc-203094 | 5 mg | $153.00 | ||
L-165041 is a PPARδ agonist. Activation of PPARδ promotes fatty acid oxidation and could enhance the activity of LSDP5 in the regulation of lipid droplet dynamics and fatty acid mobilization. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Pioglitazone, another PPARγ agonist, affects genes related to lipid metabolism. It could augment the function of LSDP5 by increasing its expression and facilitating its lipid-regulatory role in adipocytes, similar to the effects of Rosiglitazone. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $80.00 $175.00 | 28 | |
GW501516 is a PPARβ/δ activator, known for its role in lipid metabolism. By activating PPARβ/δ, it could lead to an increase in LSDP5 activity, thereby promoting lipid catabolism and utilization. | ||||||
Oleylethanolamide | 111-58-0 | sc-201400 sc-201400A | 10 mg 50 mg | $88.00 $190.00 | 1 | |
OEA activates PPARα and enhances lipid metabolism. Through PPARα activation, OEA could potentiate the activity of LSDP5, facilitating its role in the hydrolysis of stored lipids and the maintenance of energy homeostasis. | ||||||
CL 316243 disodium salt | 151126-84-0 | sc-203895 sc-203895A | 10 mg 50 mg | $510.00 $1535.00 | 15 | |
CL 316243 is a selective β3-adrenergic receptor agonist, which can stimulate lipolysis. By activating β3-adrenergic receptors, CL 316243 could indirectly enhance LSDP5 activity by promoting the breakdown of lipids that LSDP5 regulates within lipid droplets. | ||||||